Pharma in Focus
Email Address Sign-Up

Australia's most trusted source of pharma news

Buy now fake rolex


Cancer drugs win TGA nod

Posted 5 August 2021 AM

Two new provisional determinations granted by the TGA mark the first local appearance of Merck's MET inhibitor tepotinib and reveals Sanofi is seeking yet another indication for its skin cancer drug Libtayo.

Although the regulator has not disclosed the indications related to these determinations, an orphan drug designation granted to Merck's drug on the same day suggests it's for the treatment of non-small cell lung cancer (NSCLC) in patients with genetic MET alterations.

Looks like you've lost your access to Pharma in Focus. To restore access or update your subscription, click here

Approvals Action
Melb pharma registers first copy
Long list of generic versions of PBS-listed drugs